SIO Annual Scientific Meeting, January 26 – 29, 2024
January 24, 2024
Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. will be attending the SIO Annual Scientific Meeting January 26…
Spectrum Conference, January 11 – 14, 2024
January 11, 2024
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) are looking forward to attending Spectrum Conference, January…
JPM 2024 San Francisco, January 8 – 12, 2024
January 8, 2024
Our networking is well underway with investors and potential strategic partners for the JPM 2024. Attending the annual summit Lu…
Immunophotonics Announces Research Collaboration to Study Combination of Its Lead Asset with Radiotherapy
December 21, 2023
Immunophotonics Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President have announced a research collaboration with Johnson & Johnson…
AngioDynamics International Life Symposium October 26 – 28, 2023
October 25, 2023
Immunophotonics co-founders Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President attending the AngioDynamics International Life Symposium taking place…
ESMO Conference October 20 – 24, 2023
October 19, 2023
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be attending ESMO Conference, October 20 –…
ThinkEquity Conference October 19, 2023
October 18, 2023
Immunophotonics CEO Lu Alleruzzo will be participating at the ThinkEquity Conference in Mandarin Oriental, New York on October 19th. Check…
Bio Investor Forum, October 17-18, 2023
October 16, 2023
Immunophotonics Co-founder, CIO, and President Tomas Hode, PhD will be attending one of the most significant investor conferences in San…
Immunophotonics Announces First Patient Dosed in the United States under its Investigational New Drug (IND) Application
October 10, 2023
Immunophotonics CEO Lu Alleruzzo announced, along with Dr. Robert CG Martin II, M.D, PhD, PACS, who serves as the Principal…
Immunophotonics’ Fast-Track Grant from NIH’s National Cancer institute was granted approval to transition from Phase I to Phase II
September 26, 2023
Immunophotonics was recently granted approval by the NIH’s National Cancer Institute to transition from Phase I to Phase II Fast-track…